Fractyl Health, Inc. (GUTS)
NASDAQ:GUTS
GUTS Stock Chart & Stats
$0.45
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.45
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.38 - $3.03
Previous Close$1.96
Volume269.01K
Average Volume (3M)2.47M
Market Cap
$71.17M
Enterprise Value$12.49M
Total Cash (Recent Filing)$81.54M
Total Debt (Recent Filing)$61.65M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 19, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding158,648,960
10 Day Avg. Volume2,345,119
30 Day Avg. Volume2,468,938
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.95
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$6.00Price Target Upside1233.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Efficacy And Safety SignalsRandomized and open-label analyses showing maintained or additional weight loss after stopping GLP-1 therapy, along with no serious device-related adverse events, support the procedure's durability and tolerability profile.
Pivotal Trial ValidationMidpoint results from the multicenter REMAIN-1 cohort support the trial design and increase confidence that the pivotal study can provide definitive evidence of the procedure's ability to preserve weight after GLP-1 discontinuation.
Regulatory Pathway ProgressFavorable FDA pre-submission feedback pointing to a potential De Novo pathway could enable a more efficient U.S. approval route and facilitate a regulatory submission if pivotal data are supportive.
Bears Say
Limited Data RobustnessEfficacy and safety evidence relies on a relatively small number of participants and open-label cohorts, which may limit confidence in how well results will generalize to larger, blinded studies.
Procedural Variability And Implementation RiskEarly variation in ablation length due to a procedural learning curve could produce inconsistent outcomes across operators and complicate both clinical adoption and trial reproducibility.
Statistical Significance And Efficacy ConcernsMidpoint findings prompted investor sell-offs and analyst downgrades after the observed benefit missed conventional statistical thresholds, raising doubts about the strength of the demonstrated effect.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $3.03 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $71.17M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is May 19, 2026 which is in 51 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on Mar 24, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.18 by -$0.13.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.16.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.18. Following the earnings report the stock price went up 16.279%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (1233.33% Upside)
$6.00 (1233.33% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 237.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.44%
12-Months-Change
Fundamentals
Return on Equity
9999.00%
Trailing 12-Months
Asset Growth
12.33%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
GUTS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated several strong clinical, operational, regulatory, and commercial positives: a clear and biologically plausible dose-response for Revita, a fully enrolled and well-powered pivotal (>300 patients) with excellent retention and safety consistency, constructive FDA De Novo feedback, explicit reimbursement pathway planning, and a separate early-stage Rejuva program advancing without competing for capital. Financially, the company reduced R&D spend and slightly improved adjusted EBITDA, and it has cash to reach the pivotal readout. Offsetting risks include a materially larger reported net loss (largely noncash), a relatively short runway beyond early 2027, prior study pauses, and sensitivity of outcomes to procedural dose/training observed in the Midpoint Cohort. On balance, the positive clinical and regulatory progress and preparedness for commercialization materially outweigh the financial and operational risks described.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$6.00
▲(1233.33% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
7.56% Insiders
4.73% Mutual Funds
55.33% Other Institutional Investors
28.35% Public Companies and Individual Investors
Options Prices
Currently, No data available
---